Mini oral session - Gastrointestinal tumours, non-colorectal

LBA52 - Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study

Date

17 Sep 2021

Session

Mini oral session - Gastrointestinal tumours, non-colorectal

Presenters

Lin Shen

Citation

Annals of Oncology (2021) 32 (suppl_5): S1283-S1346. 10.1016/annonc/annonc741

Authors

L. Shen¹, Z. Lu², J. Wang³, Y. Shu⁴, L. Kong⁵, L. Yang⁶, B. Wang⁷, Z. Wang⁸, Y. Ji⁹, G. Cao¹⁰, H. Liu¹¹, T. Cui¹², N. Li¹³, W. Qiu¹⁴, Z. Ma¹⁵, Y. Chen¹⁵, H. Li¹⁶, X. Sun¹⁶, Y. Wang¹⁵, H. Zhou¹⁵

Author affiliations

¹ Key Laboratory Of Carcinogenesis And Translational Research (ministry Of Education), Peking University Cancer Hospital and Institute, 100000 - Beijing/CN
² Department Of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, 100000 - Beijing/CN
³ Department Of Oncology, The Affiliated Hospital of Jining Medical College, Jining/CN
⁴ Department Of Medical Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing/CN
⁵ Special Needs Ward, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan/CN
⁶ Department Of Medical Oncology, Nantong Cancer Hospital, Nantong/CN
⁷ Department Of Medical Oncology, Northern Jiangsu People's Hospital, Affiliated Hospital to Yangzhou University, Yangzhou/CN
⁸ Department Of Radiotherapy And Chemotherapy, Tangshan People Hospital, Tangshan/CN
⁹ Department Of Medical Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang/CN
¹⁰ Department Of Oncology, Jiangsu Cancer Hospital, Nanjing Medical University, Nanjing/CN
¹¹ Department Of Medical Oncology, Anhui provincial Cancer Hospital, University of Science and Technology of China, Hefei/CN
¹² Department Of Oncology, Fujian Provincial Hospital, Fuzhou/CN
¹³ Department Of Medical Oncology, Suining Central Hospital, Suining/CN
¹⁴ Department Of Medical Oncology, The Affiliated Hospital of Qingdao University, Qingdao/CN
¹⁵ Medical Oncology, Innovent Biologics, Inc., Suzhou/CN
¹⁶ Biostatistics, Innovent Biologics, Inc., Suzhou/CN

Resources

Abstract LBA52

Background

ORIENT-15 is a global, randomized, double-blind study to evaluate the efficacy and safety of sintilimab + chemo (S+C) vs chemo (C) as first-line (1L) treatment in patients (pts) with unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).

Methods

Eligible pts were randomized 1:1 to sintilimab/placebo 200 mg Q3W for up to 24 months +chemo (TP: paclitaxel 175 mg/m² Q3W + cisplatin 75 mg/m² Q3W or CF: cisplatin 75 mg/m² Q3W+5-FU 800 mg/m² on d1-5 Q3W). Randomization was stratified by ECOG PS (0 vs 1), liver metastasis (presence vs absence), chemo regimen (TP vs CF). Treatment continued until progression, unacceptable toxicity or withdrawal. No crossover was permitted. The primary end points were OS in the pts with PD-L1 combined positive score (CPS) ≥10 and all pts. The secondary endpoints were PFS and ORR (RECIST v1.1; by investigator) in the pts with PD-L1 CPS ≥10 and all pts. Data cutoff for interim analysis was Apr 9, 2021.

Results

At data cutoff, 659 pts (86% male, 97% Chinese, 87% metastatic) were randomized (327 S+C, 332 C). Median follow-up was 11.4 months. Sintilimab + chemo vs chemo was superior for OS in all pts (median 16.7 vs 12.5 mo, HR 0.628, 95% CI 0.508-0.777, P < 0.0001) and CPS ≥10 pts (median 17.2 vs 13.6 mo, HR 0.638, 95% CI 0.480-0.848, P =0.0018). PFS was superior with S+C vs C in all pts (median 7.2 vs 5.7 mo, HR 0.558, 95% CI 0.461-0.676, P <0.0001) and CPS ≥10 pts (median 8.3 vs 6.4 mo, HR 0.580, 95% CI 0.449-0.749, P <0.0001). ORR was 75.5 vs 56.9% in all pts, with median DOR of 8.3 vs 5.6 mo. ORR was 78.7 vs 57.5% in CPS ≥10 pts, with median DOR of 8.5 vs 5.5 mo. Of pts receiving at least one drug dose, treatment-related adverse events (TRAEs) rates were 98.2% vs 98.2%. Grade ≥3 TRAEs rates were 59.9% vs 54.5%. Discontinuation rates from TRAEs were 20.8% vs 12.3%. Death rates from TRAEs were 2.8% vs 1.8%.

Conclusions

OS, PFS and ORR are all significantly improved in S+C vs C, with a manageable safety profile in the pts with PD-L1 CPS ≥10 and all pts. Especially the HR of OS is less than 0.7 in all pts. The results demonstrate that the combination of sintilimab and chemo can be considered as a new 1L treatment in patients with advanced or metastatic ESCC.

Clinical trial identification

NCT03748134.

Editorial acknowledgement

Legal entity responsible for the study

Innovent Biologics, Inc., China.

Funding

Innovent Biologics, Inc., China & Eli Lilly and Company, US.

Disclosure

L. Shen: Non-Financial Interests, Institutional, Principal Investigator: Innovent Biologics, Inc.Z. Lu: Non-Financial Interests, Institutional, Principal Investigator: Innovent Biologics, Inc. J. Wang: Non-Financial Interests, Institutional, Principal Investigator: Innovent Biologics, Inc. Y. Shu: Non-Financial Interests, Institutional, Principal Investigator: Innovent Biologics, Inc. L. Kong: Non-Financial Interests, Institutional, Principal Investigator: Innovent Biologics, Inc. L. Yang: Non-Financial Interests, Institutional, Principal Investigator: Innovent Biologics, Inc. B. Wang: Non-Financial Interests, Institutional, Principal Investigator: Innovent Biologics, Inc. Z. Wang: Non-Financial Interests, Institutional, Principal Investigator: Innovent Biologics, Inc. Y. Ji: Non-Financial Interests, Institutional, Principal Investigator: Innovent Biologics, Inc. G. Cao: Non-Financial Interests, Institutional, Principal Investigator: Innovent Biologics, Inc. H. Liu: Non-Financial Interests, Institutional, Principal Investigator: Innovent Biologics, Inc. T. Cui: Non-Financial Interests, Institutional, Principal Investigator: Innovent Biologics, Inc. N. Li: Non-Financial Interests, Institutional, Principal Investigator: Innovent Biologics, Inc. W. Qiu: Non-Financial Interests, Institutional, Principal Investigator: Innovent Biologics, Inc. Z. Ma: Financial Interests, Personal and Institutional, Full or part-time Employment: Innovent Biologics, Inc. Y. Chen: Financial Interests, Personal and Institutional, Full or part-time Employment: Innovent Biologics, Inc. H. Li: Financial Interests, Personal and Institutional, Full or part-time Employment: Innovent Biologics, Inc. X. Sun: Financial Interests, Personal, Full or part-time Employment: Innovent Biologics, Inc. Y. Wang: Financial Interests, Personal, Full or part-time Employment: Innovent Biologics, Inc. H. Zhou: Financial Interests, Personal, Full or part-time Employment: Innovent Biologics, Inc.